Euroopan unioni - tšekki - EMA (European Medicines Agency)

nabriva therapeutics ireland dac - lefamulin acetate - pneumonia, bacterial; community-acquired infections - antibakteriální látky pro systémové použití, - xenleta is indicated for the treatment of community-acquired pneumonia (cap) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of cap or when these have failed. pozornost by měla být věnována oficiálním doporučením pro správné používání antibakteriálních látek.

Euroopan unioni - tšekki - EMA (European Medicines Agency)

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastická činidla - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.

Euroopan unioni - tšekki - EMA (European Medicines Agency)

gedeon richter plc. - relugolix, norethisterone acetate, estradiol hemihydrate - leiomyom - hypofýzy a hypotalamické hormony a analogy - ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Euroopan unioni - tšekki - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - imunosupresiva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Euroopan unioni - tšekki - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastická činidla - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

ardez pharma, spol. s r.o., kosoř array - 11275 drospirenon; 578 ethinylestradiol - potahovaná tableta - 3mg/0,03mg - drospirenon a ethinylestradiol

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

adamed pharma s.a., czosnów array - 578 ethinylestradiol; 11275 drospirenon - potahovaná tableta - 0,02mg/3mg - drospirenon a ethinylestradiol

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

aristo pharma gmbh, berlin array - 578 ethinylestradiol; 9125 dienogest - potahovaná tableta - 2mg/0,03mg - dienogest a ethinylestradiol

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

gedeon richter plc., budapešť array - 578 ethinylestradiol; 308 chlormadinon-acetÁt - potahovaná tableta - 0,03mg/2mg - chlormadinon a ethinylestradiol

Tšekki - tšekki - SUKL (Státní ústav pro kontrolu léčiv)

aristo pharma gmbh, berlin array - 19614 mikronizovanÝ desogestrel; 19414 mikronizovanÝ ethinylestradiol - potahovaná tableta - 0,15mg/0,02mg - desogestrel a ethinylestradiol